Verona Pharma plc VRNA
106.91 0.00 (+0.00%)
At closeOct 7, 2025, 4:00 PM EDT
106.91 Day range 106.91
31.60 52-week range 106.93
- YTD
- +130.21%
- 1 year
- +233.99%
- Market cap
- 9.09B
- Revenue (ttm)
- 221.67M
- Profit margin
- -36.63%
- EPS (ttm)
- -1.04
- Shares out
- 84.98M
- P/E ratio
- 872.73
- Forward P/E
- -381.82
- YTD return
- +130.21%
- 1-year return
- +233.99%
- Volume
- 1.87M
- Avg volume
- 1.69M
- Open
- 106.91
- Previous close
- 106.91
- Day's range
- 106.91 – 106.91
- 52-week range
- 31.60 – 106.93
- Beta
- 0.05
- Analysts
- Hold
- Earnings date
- Nov 3, 2025
YTD +58.71 (+121.80%)
Key statistics
- Enterprise value
- 73.52B
- PEG ratio
- 0.00
- Price / sales
- 40.98
- Price / book
- 33.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -57.39M
- Total cash
- 438.02M
- Total debt
- 244.37M
- Return on equity
- -36.36%
- Short % of float
- 2.44%
- 50-day average
- 105.95
- 200-day average
- 79.84
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 3, 2025
Expected Nov 3, 2025. Consensus EPS estimate 0.00.
Financials — quick view
VRNA Revenue — quarterly 103.14M
VRNA Net income — quarterly 11.92M
VRNA EPS — quarterly 0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2025 | Sep 1, 2025 | 0.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Jul 10, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 10, 2025 | BTIG | down | Buy | Neutral |
| Jul 9, 2025 | Jefferies | down | Buy | Hold |
| Jul 9, 2025 | Canaccord Genuity | down | Buy | Hold |
| Jul 1, 2025 | Wolfe Research | init | — | Outperform |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- veronapharma.com
News
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio 
Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing 
The Year-End 2025 Biotech Rally And What It Means For 2026 
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio 
Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA 
Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday 
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales 
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck 
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Your note
Sign in to keep a note on VRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMANN CHRISTINA M | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| AUSTWICK MICHAEL | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| DESCHAMPS LISA | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| EDWARDS MARTIN | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| HAHN MARK W | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| RICKARD KATHLEEN A | Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.12% | 6,134,405 | 655.83M | Jun 29, 2025 |
| Perceptive Advisors Llc | 6.39% | 5,507,591 | 588.82M | Jun 29, 2025 |
| Darwin Global Management, Ltd. | 4.79% | 4,129,618 | 441.50M | Jun 29, 2025 |
| Frazier Life Sciences Management, L.P. | 3.93% | 3,383,950 | 361.78M | Jun 29, 2025 |
| RTW Investments LP | 3.54% | 3,051,878 | 326.28M | Jun 29, 2025 |
| Eventide Asset Management LLC | 3.15% | 2,715,324 | 290.30M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 2.19% | 1,889,627 | 202.02M | Jun 29, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.57% | 1,357,044 | 145.08M | Jun 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.09% | 936,802 | 100.15M | Jun 29, 2025 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 0.95% | 820,644 | 87.74M | Jul 30, 2025 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.94% | 809,112 | 86.50M | Jun 29, 2025 |
| Putnam Funds Trust-Putnam Small Cap Growth Fund | 0.85% | 734,132 | 78.49M | Jun 29, 2025 |